Generic Name and Formulations:
Erythromycin (as base) 333mg, 500mg; particles in tabs.
Arbor Pharmaceuticals, LLC
Indications for PCE:
Susceptible infections including upper and lower respiratory, skin and soft tissue, genitourinary, Legionnaires' disease, pertussis, listeriosis.
Preferably take 2hrs before meals. Usually 333mg every 8hrs or 500mg every 12hrs. Genitourinary: two 333mg tabs every 8hrs or 500mg 4 times daily for 7 days. Legionnaires: 1–4g daily in divided doses. Max 4g daily; twice daily dosing max 1g/day.
Preferably give 2hrs before meals. Mild-to-moderate infections: 30–50mg/kg/day; may double dose in severe infections. Both in divided doses. Max 4g daily.
Concomitant cisapride, pimozide, ergotamine, dihydroergotamine.
Hepatic dysfunction. Proarrhythmic conditions (eg, uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia); QT prolongation may occur, avoid. Myasthenia gravis. Elderly. Pregnancy (Cat.B). Nursing mothers.
See Contraindications. May potentiate or be potentiated by drugs metabolized by CYP3A (eg, carbamazepine, cyclosporine, tacrolimus, alfentanil, disopyramide, bromocriptine, rifabutin, quinidine, methylprednisolone, cilostazol, vinblastine). May potentiate or be potentiated by hexobarbital, phenytoin, valproate. May potentiate triazolam, midazolam, digoxin, theophylline, statins (rhabdomyolysis), sildenafil (reduce dose of sildenafil), colchicine (reduce starting dose of colchicine, max dose should be lowered; monitor). Hypotension, bradyarrhythmias, lactic acidosis with verapamil. Hypotension with calcium channel blockers metabolized by CYP3A4 (eg, verapamil, amlodipine, diltiazem). Increased anticoagulant effects with oral anticoagulants. QT prolongation with concomitant Class 1A (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmics. May interfere with fluorometric detection of urinary catecholamines.
GI upset, abdominal pain, anorexia, hepatic dysfunction; QT prolongation.
Tabs 333mg—60; 500mg—100
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma
- CLL: Venetoclax Plus Rituximab Improves 2-Year PFS
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma